SSG
BNTX icon

Summit Securities Group’s BioNTech BNTX Stock Holding History

Summit Securities Group’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$114 – 819
2024
Q4 		$114 Buy
+1
New +$114 ﹤0.01% 572

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Summit Securities Group's BNTX Position: Q1 2025 in Review

Summit Securities Group sold out of BioNTech (BNTX) in Q1 2025, closing a stake of 1 share — an estimated $114 sold.

Summit Securities Group first reported a position in BNTX in Q4 2024 and held it in 1 quarter. The position peaked at $114 in Q4 2024. 280 funds tracked by Wall St. Rank hold BNTX as of Q1 2025.

  • Summit Securities Group reported no remaining BioNTech position as of Q1 2025 after selling out during the quarter.
  • Summit Securities Group sold 1 BioNTech share in Q1 2025, an estimated $114.
  • Summit Securities Group first reported a position in BioNTech in Q4 2024 and held it in 1 quarter.
  • Summit Securities Group's BioNTech position peaked at $114 in Q4 2024.
  • 280 funds tracked by Wall St. Rank held BioNTech as of Q1 2025.

Based on Summit Securities Group's 13F filing for Q1 2025, filed 13 May 2025.